Inactive Instrument

Genentech, Inc. Share Price

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

2015	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
2009	GENENTECH : Roche buys Genentech for $46.8 billion	RE

Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	16/02/15	CI
GENENTECH : Roche buys Genentech for $46.8 billion	12/03/09	RE
GENENTECH : Roche increases Genentech offer to $45.7 billion	06/03/09	RE
GENENTECH : gives long-term forecast to fend off Roche	02/03/09	RE
GENENTECH : to make case for higher purchase price	27/02/09	RE
GENENTECH : asks shareholders to hold off on Roche bid	10/02/09	RE
GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	30/01/09	RE
GENENTECH : forecast disappoints	15/01/09	RE
GENENTECH : profit up, forecast light	15/01/09	RE
GENENTECH : profit rises, sales top estimates	14/10/08	RE
GENENTECH : 3rd-quarter profit rises	14/10/08	RE
GENENTECH : rejects Roche bid but willing to talk	13/08/08	RE
GENENTECH : rejects Roche bid	13/08/08	RE

Genentech, Inc. : Dalradian Appoints Chief Operating Officer	20/04/11	PU
Genentech, Inc. : Dalradian Appoints Chief Operating Officer	20/04/11	PU
GENENTECH : Roche Completes Acquisition of Genentech	26/03/09	PR
GENENTECH : Roche Completes Tender Offer for Genentech	26/03/09	PR
GENENTECH : Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation	12/03/09	PR

Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie	12/04/16
Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art	11/04/16
Genentech : Roche détient 93,2% du capital.	26/03/09
GENENTECH : Roche détient 93,2% de Genentech à l'issue de son offre	26/03/09
GENENTECH : Roche parvient à ses fins avec Genentech	12/03/09

Sector